Recent Advances in the Development of Dopamine D3 Receptor Antagonists: a Medicinal Chemistry Perspective

Dopamine (DA) D3 receptor antagonism might play a significant role in different therapeutic areas. A high number of preclinical studies on DA D3 receptor antagonists have shown efficacy in animal models of Parkinson’s disease, schizophrenia and drug dependence. This Review covers the activities of medicinal chemists in this field over the last ten years towards the identification of truly selective compounds. Both primary and patent literature is reviewed here. Since the original discoveries, a clear trend towards the optimization of the developability properties of the new scaffold has clearly emerged with time, from both academic and industrial researchers. Examples of advanced leads from academia and industry are described. The latest potential therapeutic applications are reported too.

[1]  M. Nader,et al.  Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. , 2005, Journal of medicinal chemistry.

[2]  C. Heidbreder,et al.  Selective dopamine D3 receptor antagonists: a review 2001-2005. , 2006, Recent patents on CNS drug discovery.

[3]  E. Bézard,et al.  The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. , 2006, CNS & neurological disorders drug targets.

[4]  18F‐Labeled FAUC 346 and BP 897 Derivatives as Subtype‐Selective Potential PET Radioligands for the Dopamine D3 Receptor , 2008, ChemMedChem.

[5]  Susanta K. Sarkar,et al.  Imaging brain regional and cortical laminar effects of selective D3 agonists and antagonists , 2010, Psychopharmacology.

[6]  Harald Hübner,et al.  Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists. , 2002, Journal of medicinal chemistry.

[7]  New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems. , 2008, Bioorganic & medicinal chemistry letters.

[8]  Daniel M. Lowe,et al.  ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters. , 2009, Bioorganic & medicinal chemistry.

[9]  J. Schwartz,et al.  Parallel synthesis and dopamine D3/D2 receptor screening of novel {4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}carboxamides. , 2005, Bioorganic & Medicinal Chemistry.

[10]  P. Gmeiner,et al.  A Series of 18F‐Labelled Pyridinylphenyl Amides as Subtype‐Selective Radioligands for the Dopamine D3 Receptor , 2010, ChemMedChem.

[11]  B. Everitt,et al.  Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist , 1999, Nature.

[12]  A. Newman,et al.  Characterization of the Transport, Metabolism, and Pharmacokinetics of the Dopamine D3 Receptor-Selective Fluorenyl- and 2-Pyridylphenyl Amides Developed for Treatment of Psychostimulant Abuse , 2010, Journal of Pharmacology and Experimental Therapeutics.

[13]  P. Sokoloff,et al.  N-(ω-(4-(2-Methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as Dopamine D2 and D3 Receptor Ligands , 2003 .

[14]  L. Unger,et al.  Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists: variations on the 1H-pyrimidin-2-one theme. , 2006, Bioorganic & medicinal chemistry letters.

[15]  P. Gmeiner,et al.  Synthesis and evaluation of 18F-labeled dopamine D3 receptor ligands as potential PET imaging agents. , 2005, Bioorganic & medicinal chemistry letters.

[16]  Y. Cho,et al.  Design and synthesis of a piperazinylalkylisoxazole library for subtype selective dopamine receptor ligands. , 2002, Bioorganic & medicinal chemistry letters.

[17]  Dopamine D3 Receptor Ligands with Antagonist Properties , 2002, Chembiochem : a European journal of chemical biology.

[18]  S. Melotto,et al.  Delay of ejaculation induced by SB-277011, a selective dopamine D3 receptor antagonist, in the rat. , 2009, The journal of sexual medicine.

[19]  Paul D Leeson,et al.  Time-related differences in the physical property profiles of oral drugs. , 2004, Journal of medicinal chemistry.

[20]  M. Millan,et al.  S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. , 2000, The Journal of pharmacology and experimental therapeutics.

[21]  E. Lacivita,et al.  Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands with optimal lipophilicity for brain imaging of the dopamine D3 receptor. Part II. , 2009, Bioorganic & medicinal chemistry.

[22]  A. Newman,et al.  Evaluation of the D3 dopamine receptor selective antagonist PG01037 on l-dopa-dependent abnormal involuntary movements in rats , 2009, Neuropharmacology.

[23]  A. Capelli,et al.  Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists. , 2010, Journal of medicinal chemistry.

[24]  Erin E. Carlson,et al.  Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. , 2005, Journal of medicinal chemistry.

[25]  G. Schneider,et al.  GPCR Targeted Library Design: Novel Dopamine D3 Receptor Ligands , 2007, ChemMedChem.

[26]  M. Nader,et al.  Effects of Two Novel D3-Selective Compounds, NGB 2904 [N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide] and CJB 090 [N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide], on the Reinforcing and Discriminative Stimulus Effects of Cocaine in Rhesus M , 2007, Journal of Pharmacology and Experimental Therapeutics.

[27]  A. Prandi,et al.  [3-azabicyclo[3.1.0]hex-1-yl]phenyl-benzenesulfonamides as selective dopamine D3 antagonists. , 2010, Bioorganic & medicinal chemistry letters.

[28]  Jonathan A. Javitch,et al.  Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.

[29]  Robert R Luedtke,et al.  N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. , 2009, Journal of medicinal chemistry.

[30]  Deepak Dalvie,et al.  Aldehyde oxidase: an enzyme of emerging importance in drug discovery. , 2010, Journal of medicinal chemistry.

[31]  John D. Beaver,et al.  Imaging Dopamine D3 Receptors in the Human Brain with Positron Emission Tomography, [11C]PHNO, and a Selective D3 Receptor Antagonist , 2010, Biological Psychiatry.

[32]  Bruno Giros,et al.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.

[33]  L. Unger,et al.  Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists: Quinolin(di)one and benzazepin(di)one derivatives , 2006 .

[34]  P. Leeson,et al.  A comparison of physiochemical property profiles of development and marketed oral drugs. , 2003, Journal of medicinal chemistry.

[35]  Angelo Bifone,et al.  Pharmacological modulation of functional connectivity: the correlation structure underlying the phMRI response to d-amphetamine modified by selective dopamine D3 receptor antagonist SB277011A. , 2007, Magnetic resonance imaging.

[36]  J. Hagan,et al.  1,2,4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines: A Series of Potent and Selective Dopamine D3 Receptor Antagonists , 2007 .

[37]  L. Gitajn,et al.  The Novel Dopamine D3 Receptor Antagonist NGB 2904 Inhibits Cocaine's Rewarding Effects and Cocaine-Induced Reinstatement of Drug-Seeking Behavior in Rats , 2006, Neuropsychopharmacology.

[38]  M. Gleeson.  Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.

[39]  M. Millan,et al.  Dopamine D3 receptor antagonists as therapeutic agents. , 2005, Drug discovery today.

[40]  P. Gmeiner,et al.  1,1'-Disubstituted ferrocenes as molecular hinges in mono- and bivalent dopamine receptor ligands. , 2009, Journal of medicinal chemistry.

[41]  J. Hagan,et al.  Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. , 2000, The Journal of pharmacology and experimental therapeutics.

[42]  Francesco Berardi,et al.  Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands for visualization of brain dopamine D3 receptors. , 2006, Journal of medicinal chemistry.

[43]  A. Kling,et al.  Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists: 1H-Pyrimidin-2-one derivatives , 2006 .

[44]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[45]  B. Gulyás,et al.  Lack of effect of reserpine-induced dopamine depletion on the binding of the dopamine-D3 selective radioligand, [11C]RGH-1756 , 2005, Brain Research Bulletin.

[46]  J. Schneider,et al.  The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. , 2010, The international journal of neuropsychopharmacology.

[47]  C. Lipinski.  Lead- and drug-like compounds: the rule-of-five revolution. , 2004, Drug discovery today. Technologies.

[48]  A. Capelli,et al.  1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists. , 2010, Journal of medicinal chemistry.

[49]  M Paul Gleeson,et al.  Plasma protein binding affinity and its relationship to molecular structure: an in-silico analysis. , 2007, Journal of medicinal chemistry.

[50]  B. Le Foll,et al.  The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking. , 2010, The international journal of neuropsychopharmacology.

[51]  New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems. , 2008, Bioorganic & medicinal chemistry letters.

[52]  F. Boeckler,et al.  Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of heterocyclic dopamine D3 receptor agonists. , 2005, Journal of medicinal chemistry.

[53]  Yiyun Huang,et al.  Dopamine D3 receptor antagonists: the quest for a potentially selective PET ligand. Part 3: Radiosynthesis and in vivo studies. , 2009, Bioorganic & medicinal chemistry letters.

[54]  Ji-Kyung Choi,et al.  Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. , 2007, Journal of medicinal chemistry.

[55]  F. Boeckler,et al.  Fancy bioisosteres: metallocene-derived G-protein-coupled receptor ligands with subnanomolar binding affinity and novel selectivity profiles. , 2005, Journal of medicinal chemistry.

[56]  A. Newman,et al.  Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders , 2010, Annals of the New York Academy of Sciences.

[57]  Torsten Kuwert,et al.  Structure-selectivity investigations of D2-like receptor ligands by CoMFA and CoMSIA guiding the discovery of D3 selective PET radioligands. , 2007, Journal of medicinal chemistry.

[58]  Dopamine D(3) receptor antagonists: The quest for a potentially selective PET ligand. Part two: Lead optimization. , 2009, Bioorganic & medicinal chemistry letters.

[59]  G. Hutchins,et al.  Synthesis of new carbon-11-labeled carboxamide derivatives as potential PET dopamine D3 receptor radioligands. , 2008, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[60]  Xueliang Fang,et al.  Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. , 2003, Journal of medicinal chemistry.

[61]  M Paul Gleeson,et al.  In silico human and rat Vss quantitative structure-activity relationship models. , 2006, Journal of medicinal chemistry.

[62]  A. Capelli,et al.  Triazolyl Azabicyclo[3.1.0]hexanes: a Class of Potent and Selective Dopamine D3 Receptor Antagonists , 2010, ChemMedChem.

[63]  Yong Seo Cho,et al.  Classification of dopamine antagonists using functional feature hypothesis and topological descriptors. , 2006, Bioorganic & medicinal chemistry.

[64]  C. Heidbreder,et al.  Selective dopamine D3 receptor antagonists. A decade of progress: 1997 – 2007 , 2008 .